Biomea Fusion Q2 loss narrows, cash runway into Q2 2027

Biomea Fusion

05/08/2026 21:47

Overview
US diabetes and obesity drug developer's Q2 net loss narrowed from prior year
Lower R&D and G&A expenses drove reduced net loss in Q2
Company projects cash runway into Q2 2027

Outlook
Biomea Fusion expects initial obesity trial data in Q3 2026
Company sees diabetes trial data in Q1 and Q2 2027
Cash runway projected into Q2 2027

Result Drivers
CLINICAL TRIAL PROGRESS - Co said continued enrollment and advancement of Phase II and Phase I trials in diabetes and obesity drove activity in Q2
COST REDUCTIONS - Lower R&D and G&A expenses driven by reduced headcount, external costs, and facility expenses contributed to narrowed net loss
RESEARCH COLLABORATION - Co initiated collaboration with University of Leicester to evaluate icovamenib with semaglutide in obesity

Company press release: ID:nGNX7hSJv0

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$8.30 mln
 
Q2 Loss Per Basic Share
 
$0.12
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Biomea Fusion, Inc. is $7.00, about 469.1% above its August 4 closing price of $1.23

Reuters Recommended Reads
Aug 5 - Lilly beats estimates on resilient demand for injectable GLP-1 drugs, widens gap with Novo
Aug 4 - Novo Nordisk Q2 lifts FY guidance on stronger GLP-1 demand
Aug 5 - Entrada Therapeutics Q2 net loss narrows on lower costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)